Uterine Artery Embolization (UAE) for Fibroids

Overview

Uterine artery embolization (UAE), also called uterine fibroid embolization, is a minimally‑invasive radiologic procedure that blocks the blood supply to uterine fibroids, causing them to shrink and symptoms to improve. The technique uses tiny particles injected through a catheter placed in the uterine arteries. UAE is an alternative to surgical options such as myomectomy or hysterectomy.

Who it affects: Fibroids are most common in women of reproductive age. By age 50, up to 70–80 % of women have fibroids (CDC, 2023). Not all require treatment; UAE is typically considered for women who have symptomatic fibroids and who wish to avoid major surgery or preserve the uterus.

Prevalence of UAE: In the United States, more than 150,000 UAE procedures have been performed since its FDA approval in 2000, with an average of ~6,000–8,000 procedures per year in recent years (Society of Interventional Radiology, 2022).

Symptoms

Fibroids can cause a wide range of symptoms, varying by size, number, and location. The most common symptoms that lead patients to seek treatment—including UAE—are:

• Heavy menstrual bleeding (menorrhagia): soaking through pads or tampons every hour, passing clots larger than a quarter.
• Prolonged periods: cycles > 7 days.
• Pain or pressure: a dull ache in the lower abdomen, pelvis, or lower back; sometimes sharp cramping.
• Bulk symptoms: feeling of fullness, frequent urination, constipation, or difficulty emptying the bladder due to uterine enlargement.
• Infertility or recurrent pregnancy loss: fibroids that distort the cavity can interfere with implantation.
• Dyspareunia: pain during sexual intercourse, especially with posterior or large subserosal fibroids.
• Acute symptomatic fibroid degeneration: sudden sharp pain, fever, or vomiting when a fibroid outgrows its blood supply.

Less common but noteworthy symptoms include anemia (due to chronic blood loss) and, rarely, palpable abdominal mass.

Causes and Risk Factors

Fibroids are benign smooth‑muscle tumors of the uterus. Their exact cause is unknown, but several factors appear to promote their growth:

• Hormonal influences: Estrogen and progesterone stimulate fibroid proliferation; they often grow during pregnancy and shrink after menopause.
• Genetic predisposition: First‑degree relatives with fibroids increase personal risk by roughly 2‑3 times.
• Race/ethnicity: African‑American women develop fibroids at younger ages, have larger and more numerous fibroids, and are 2–3 times more likely to undergo UAE or hysterectomy (NIH, 2022).
• Age: Incidence rises rapidly after menarche, peaks in the 30s–40s, and declines after menopause.
• Body mass index (BMI): Obesity (BMI ≥ 30) is linked to increased fibroid risk, possibly via higher peripheral estrogen production.
• Dietary factors: High red‑meat consumption and low intake of green vegetables and fruits have been associated with higher fibroid risk.
• Early menarche & late menopause: Longer lifetime exposure to estrogen.

Diagnosis

Diagnosis begins with a thorough history and physical exam, followed by imaging to characterize size, number, and location of fibroids.

Imaging Modalities

• Transvaginal or pelvic ultrasound: First‑line, inexpensive, and highly sensitive for detecting fibroids.
• Magnetic resonance imaging (MRI): Gold standard for pre‑UAE planning; provides detailed mapping, assesses fibroid vascularity, and distinguishes adenomyosis.
• Computed tomography (CT): Used rarely; involves radiation, not preferred for young women.

Laboratory Tests

• Complete blood count (CBC) to evaluate anemia.
• Pregnancy test (UAE is contraindicated in pregnancy).
• Coagulation profile if the patient is on anticoagulants.

Eligibility Assessment

Before UAE, interventional radiologists assess:

• Uterine size and fibroid location (submucosal fibroids may be less amenable).
• Desire for future fertility (UAE can affect ovarian reserve; discuss alternatives).
• Overall health and ability to tolerate mild sedation.

Treatment Options

Fibroid management is individualized. Options range from watchful waiting to pharmacologic therapy, minimally‑invasive procedures, and surgery.

Medical Management

• GnRH agonists (e.g., leuprolide): Induce a hypo‑estrogenic state, shrinking fibroids temporarily; used pre‑operatively.
• Selective progesterone receptor modulators (e.g., ulipristal): Reduce size and bleeding; limited long‑term use due to liver‑safety warnings.
• Tranexamic acid & NSAIDs: Control heavy bleeding and pain.
• Long‑acting hormonal IUD (levonorgestrel): Reduces menstrual blood loss but does not shrink large fibroids.

Procedural Options

• Uterine artery embolization (UAE): The focus of this guide; outpatient, 1–2 hour procedure with ~80‑90 % symptom improvement.
• MRI‑guided focused ultrasound (MRgFUS): Non‑invasive, uses high‑intensity sound waves; limited availability.
• Hysteroscopic myomectomy: Removes submucosal fibroids via the cervix; preserves uterus.
• Laparoscopic or robotic myomectomy: Surgical removal of intramural/subserosal fibroids.
• Hysterectomy: Definitive; considered when other options fail or when fibroids are extensive.

Lifestyle & Supportive Measures

• Iron supplementation for anemia.
• Regular aerobic exercise to maintain healthy weight.
• Diet rich in fruits, vegetables, and whole grains; limit red meat and alcohol.
• Stress‑reduction techniques (yoga, meditation) that may improve pain perception.

Living with Uterine Artery Embolization (Procedure for Fibroids)

UAE is a day‑case or short‑stay procedure. Post‑procedure care focuses on recovery and monitoring.

• Immediate recovery (first 24 hours): Expect mild cramping, low‑grade fever, and spotting. Over‑the‑counter ibuprofen or acetaminophen usually suffices for pain.
• Activity: Light walking is encouraged; avoid heavy lifting or strenuous exercise for 1–2 weeks.
• Return to work: Most women resume sedentary jobs within 3–5 days, but office or physical‑labor jobs may need 1–2 weeks.
• Menstruation: Periods may become lighter or irregular for the first 2–3 months; normal cycles usually return by 6 months.
• Follow‑up imaging: MRI at 3–6 months to document fibroid shrinkage (average reduction 30‑50 %).
• Fertility considerations: Pregnancy after UAE is possible, but data show a slightly higher risk of miscarriage and placental abnormalities; discuss options with a maternal‑fetal medicine specialist.
• Emotional health: Many women experience relief, but some may feel anxiety about future fertility or symptom recurrence. Support groups and counseling can be helpful.

Prevention

Because the exact cause of fibroids is unknown, “prevention” focuses on modifiable risk factors that may reduce development or growth:

• Maintain a healthy BMI (18.5–24.9). Weight loss of 5–10 % can lower estrogen levels.
• Adopt a diet rich in cruciferous vegetables (broccoli, kale) and low in processed red meat.
• Limit alcohol (≤ 1 drink/day) and caffeine, which may influence hormone metabolism.
• Use combined oral contraceptives or progestin‑only options if indicated, as they can reduce menstrual bleeding and may modestly limit fibroid growth.
• Regular physical activity (150 min/week moderate intensity) helps regulate hormone balance.
• Screen for and treat hypertension and diabetes, conditions associated with larger fibroids.

While these steps cannot guarantee avoidance of fibroids, they support overall reproductive health.

Complications

If symptomatic fibroids remain untreated, several complications can arise:

• Severe anemia: Chronic blood loss may require transfusion.
• Infertility or recurrent miscarriage: Distorted uterine cavity or impaired implantation.
• Pelvic organ prolapse: Large fibroids can weaken pelvic support structures.
• Acute fibroid degeneration: Sudden pain, fever, and leukocytosis; may mimic infection.
• Urinary retention or hydronephrosis: Compression of ureters.
• Psychological impact: Chronic pain and heavy bleeding can lead to depression or reduced quality of life.

When to Seek Emergency Care

Prompt evaluation can prevent serious outcomes such as infection, uterine necrosis, or hemorrhagic shock.

---

Sources: Mayo Clinic, CDC Fibroid Fact Sheet 2023, NIH Office of Research on Women’s Health 2022, Society of Interventional Radiology Annual Report 2022, Cleveland Clinic Fibroids & UAE Overview, World Health Organization (WHO) Reproductive Health Guidelines, peer‑reviewed articles in Obstetrics & Gynecology and Radiology.